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Abstract: Helicobacter pylori (H. pylori) is a Gram-negative bacterium involved in the development
of gastritis, peptic ulcer disease, gastric adenocarcinoma, and gastric mucosa-associated lymphoid
tissue. Unexplained iron deficiency anemia, idiopathic thrombocytopenic purpura and vitamin B12
deficiency have also been related to H. pylori infection, whereas for other extra-gastric diseases, the
debate is still open. In this review, we evaluate and discuss the potential involvement of H. pylori
infection in the pathogenesis of several respiratory diseases. A MEDLINE search of all studies
published in English from 1965 to 2021 was carried out. Controversial findings have been reported
in patients with bronchial asthma, chronic obstructive pulmonary disease, bronchiectasis, lung
cancer, tuberculosis, cystic fibrosis, and sarcoidosis. Most of the available literature is concerned
with case-control studies based on seroprevalence, with a small sample size and low consideration
of confounders, which represents a potential issue. So far, there is no clear evidence of a causal
association between H. pylori infection and respiratory diseases, and larger studies with appropriate
epidemiological design are required.
Keywords: Helicobacter pylori; respiratory diseases; asthma; chronic obstructive pulmonary disease
1. Introduction
Helicobacter pylori (H. pylori) infection is globally widespread, usually acquired during
childhood, and often related to low socio-economic class [1]. Although the precise mode
of transmission remains unproven, it has been shown that such a microorganism spreads
directly from one person to another, mainly by fecal-oral or oral-oral routes [2]. This
microaerophilic, Gram-negative bacterium is usually located within the mucus layer of the
stomach, and certain ultrastructural details found on its surface (sheathed flagella and ure-
ase) are involved in its ability to survive in the surrounding hostile environment [3]. Thus,
this disproves the ancient conception of the impossibility for microorganisms to survive in
the gastric compartment due to acidity [4]. It is well known that H. pylori infection may
lead to gastritis, peptic ulcer disease (PUD), gastric adenocarcinoma and gastric mucosa-
associated lymphoid tissue (MALT) lymphoma [5], although most infected subjects remain
asymptomatic. Furthermore, in the past few years, the possible role of H. pylori in many
extra-gastric diseases has been investigated [6–8]. Among these, accumulating evidence
also supports an association with neurodegeneration [9] and nonalcoholic fatty liver dis-
ease [6], although some controversy still exists. However, only unexplained iron deficiency
anemia, idiopathic thrombocytopenic purpura, and vitamin B12 deficiency have been asso-
ciated with the latter infection, as reported in the fifth edition of the Maastricht/Florence
Consensus Report (2017) [10].
Respiratory diseases represent a leading cause of morbidity and mortality in the
world. For this reason, as stated by the World Health Organization (WHO), the prevention,
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control and cure of these diseases must be a top priority in global decision-making in the
health sector [11]. Currently, infections are the leading cause of respiratory diseases in both
children and adults, with variable outcomes depending on the causal agent as well as on
the host and environmental factors. Since known etiologic agents and risk factors explain
the pathogenesis of only a proportion of cases, investigating whether non-traditional agents
have a causal role in the pathogenetic steps of respiratory diseases is of primary importance.
Early epidemiologic studies on the relationship between H. pylori infection and res-
piratory diseases have been supported by the findings on animal models showing that
the presence of the microorganisms in the gastric compartment could be associated with
lung injury, as indicated by the increased expression of inflammatory mediators and
markers of endothelial dysfunction [12]. Over time, a series of publications, mainly re-
porting the findings of epidemiologic studies, has focused on this issue and has provided
controversial results.
The aim of this narrative review is to evaluate the consistent data available regarding
a potential involvement of H. pylori infection in the pathogenesis of respiratory diseases.
2. Materials and Methods
A MEDLINE search of all published studies from 1965 to 30 June 2021 was carried out
in order to identify all appropriate publications (Figure 1). The following medical subject
headings were used: Helicobacter pylori, Helicobacter, asthma, bronchitis, chronic obstructive
pulmonary disease or COPD, bronchiectasis, lung cancer, tuberculosis, cystic fibrosis, and
sarcoidosis. Systematic reviews and meta-analyses were used to summarize the evidence,
if available.
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3. Results
3.1. H. pylori Infection and Asthma
Bronchial asthma is a chronic inflammatory disease of the airways, characterized
by airflow obstruction and the associated presence of intermittent symptoms, including
wheezing, dyspnea, chest tightness, and coughing. The prevalence of asthma has increased
markedly in developed countries in recent years [13]. From a pathophysiological point
of view, exposure to defined allergens or to various non-specific stimuli initiates a cas-
cade of cellular activation events resulting in acute and chronic inflammatory processes
mediated by a complex assortment of locally released cytokines and other mediators.
This leads to altered airway smooth muscle responsiveness, mucus hypersecretion and
damaged epithelium.
Considering that several studies did not show a causal relationship, but often, an
inverse association between H. pylori infection and allergic asthma [14,15], a protective effect
of this microorganism against allergic diseases including asthma, especially in children
and young people, was hypothesized around fifteen years ago (the so-called “hygiene
hypothesis”). The authors associated the reduction of H. pylori prevalence with the
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rise in asthma cases as well as other allergic disorders in children, assuming a possible
relationship [16]. Over time, multiple epidemiological studies were performed on this
topic and a recent meta-analysis, including 18 observational studies with 17,196 enrolled
children, reported a significant negative association between H. pylori and the risk for
childhood asthma (odds ratio [OR] = 0.68; 95% confidence interval [CI]: 0.54–0.87; p = 0.002),
particularly in those harboring the more virulent strains (according to cytotoxin-associated
gene A [CagA] status) (OR = 0.58; 95% CI: 0.35–0.96; p = 0.034). No significant difference
among studies regarding participant age, geographical region, study design and diagnostic
method for H. pylori detection was observed [17]. In recent years, the association between
asthma or other allergic diseases and H. pylori has been intensively investigated. In a case-
control study including more than 10,000 patients, H. pylori infection was found in 31%,
asthma in 10.4%, and allergic rhinitis in 16% of them, without any significant association;
however, in patients with abdominal obesity, H. pylori infection was associated with 30-40%
reduced OR of asthma and 25% reduced OR of allergic disorders [18]. Moreover, in a
case-control study performed in Greece including 27 pediatric patients with asthma and
54 controls, an inverse association between H. pylori and asthma was confirmed (OR = 0.1;
95% CI: 0.039–0.305; p = 0.026) [19]. In a cohort study, 16% of children who were uninfected
at 2 and 10 years of age developed asthma at 16 years vs. none of the children with H. pylori
infection at 2 years of age [20] (Table 1).
A possible explanation for this inverse relationship between H. pylori and asthma,
according to the “hygiene hypothesis”, is the possibility that infectious agents can inhibit
allergic T helper (Th) 2 cells pathways, thus eliciting a Th1-type immune response. Further-
more, the neutrophil-activating protein of H. pylori (HP-NAP) increases interferon (IFN)-γ
production and decreases interleukin (IL)-4, thus driving Th1 inflammation and inhibiting
Th2 responses (Figure 2) [21]. Another possibility involves the inverse correlation between
H. pylori infection and gastroesophageal reflux disease (GERD), as the latter can worsen
asthma and this is a risk factor for developing GERD [22,23].
Nevertheless, some authors consider H. pylori only a marker of poor household hy-
giene. This stems from the evidence from studies testing the hypothesis of a protective effect
in relation to asthma in populations with poor hygiene and low H. pylori prevalence (for
example in Malaysia and Indonesia), which did not confirm this effect [24]. Furthermore,
the results of studies and consequently meta-analyses could be affected by the diagnostic
method used to diagnose H. pylori infection (mainly serology that does not discriminate
between current and past infection).
3.2. H. pylori Infection and Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease
characterized by the presence of chronic bronchitis or emphysema that may lead to the
development of airflow limitation. Acute infections, especially respiratory viral infections,
and/or exposure to pollutants are the main causes of COPD. Nevertheless, other factors
may contribute to COPD, such as the exacerbation of other respiratory diseases and non-
respiratory diseases (e.g., heart failure, thromboembolism) [25]. Whatever the cause, the
principal pathological features of chronic bronchitis are inflammation of airways and
hypertrophy of mucus glands, with increased mucus secretion and airway obstruction.
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In a Danish study, Rosenstock et al. assessed the association of H. pylori infection with
lifestyle, chronic disease, body indices, and age at menarche in 2913 adults. The authors
found a higher prevalence of chronic bronchitis in women with H. pylori seropositivity
compared to uninfected women (OR = 1.6; 95% CI: 1.1–2.5) [26]. Other studies reported
higher rates of H. pylori seropositivity in patients with COPD or chronic bronchitis [27–31]
but these were all case-controlled in design and included limited sample sizes. In a recently
published case-control study, Bener et al. reported the prevalence of H. pylori seroposi-
tivity in 529 patients with type 2 diabetes mellitus and in controls. The authors found
that the former group had a significantly higher prevalence of H. pylori compared to con-
trols. Furthermore, in diabetic patients, seropositivity was significantly associated with
chronic bronchitis (OR = 2.09; 95% CI: 1.16–3.77) [32]. In a retrospective cohort study
using data from the Taiwanese National Health Insurance Research Database and includ-
ing 5941 adults with a new diagnosis of H. pylori, the overall hazard ratio of COPD was
1.84 (95% CI = 1.57–2.17), compared to the non-H. pylori cohort, after adjusting for age,
sex, and comorbidities [33]. On the other hand, a study performed in Korea (a country
with a high prevalence of H. pylori infection) showed no differences in seroprevalence of
H. pylori between COPD patients and controls (45.8% in 201 COPD vs. 52.2% in 402 controls,
p = 0.134). Furthermore, there were no significant differences in the rate of lung function
decline (annual forced expiratory volume in 1 s or forced vital capacity [FVC]) in subjects
with COPD and airflow limitation [34]. Similarly, in a retrospective study conducted
in a health screening populatio among 3619 subjects, 1849 (51.1%) tested positive for
H. pylori immunoglobulin (Ig)G and, in the first year, 95 (2.6%) patients were diagnosed
with COPD, without any differenc in eropositivity for H. pylori compared to non-COPD
subjects (p = 0.756). There was no significant difference in the incidence of COPD e-
tween the seronegative (2.2%) and the seropositive group (2.0%; p = 0.728), and i the
decline rat s of the mean FVC and forced ex iratory volume in the first second (FEV1)
(35.38 vs. 34.34 mL/year for FVC, p = 0.389; 39.23 vs. 37.49 mL/year for FEV1, p = 0.086).
Moreover, the decline in lung function or COPD progression was not influenced by H. pylori
eradication [35]. Bennett et al. assessed in 67 lung tra spla t patients whether H. pylori
seropositivity was a sociated with thei outcome. While the overall prevalence of H. pylori
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infection in this cohort was similar to that reported in the general population, it was lower
among patients with COPD and higher among those with pulmonary fibrosis. No cor-
relation was found between H. pylori infection and graft outcome, either in patients with
pulmonary fibrosis or in those with COPD. Nevertheless, more patients who required three
or more post-transplant re-hospitalizations belonged to the H. pylori seropositive group
(p = 0.046) [36].
Table 1. Summary of the cumulative results of the main studies included.
Respiratory Disease Result Reference Publication Year
Meta-analysis of 18 studies Negative association with H.pylori infection [16] 2021
ASTHMA Case-control study including10,000 patients
Only in obese patients H.
pylori associated with 30–40%
OR of asthma ↓
[17] 2019
Cohort study
16% of children uninfected at
2 and 10 years developed
asthma at 16 years versus
none of the children with H.
















between H. pylori and COPD [32] 2017
Case-control study (Korea,
country with high burden of
H. pylori)
No association between H.
pylori and COPD [33] 2016
Samareh Fekri et al., in a cross-sectional study, evaluated the relationship between
H. pylori infection and COPD through several approaches: serologic testing for H. pylori
IgG, real-time polymerase chain reaction (PCR) of bronchoalveolar lavage (BAL) and trans-
bronchial biopsy urease tests. Sixty adults with COPD were included. The prevalence rate
of H. pylori infection was 10% according to real time PCR, 88.3% according to the serology
test and 0% based on the urease test. The relationship between H. pylori presence (based on
PCR) and disease severity and prognosis was not statistically significant. These findings
supported the hypothesis of direct injury and chronic inflammation via inhalation and
aspiration resulting in H. pylori colonization [37].
Thus, the role of H. pylori infection on the development and progression of COPD
remains unclear.
3.3. H. pylori Infection and Bronchiectasis
Bronchiectasis is an abnormal and permanent dilatation of the bronchi or their
branches, due to acute or chronic inflammation, and destruction of the elastic and muscular
tissue of the bronchial wall. This disease may be caused by cystic fibrosis, past severe
infections, genetic diseases like α-1 antitrypsin, allergic aspergillosis or immune system
diseases. Sometimes, the cause remains unexplained, configuring the picture of idiopathic
disease [38,39].
In this context, it has been hypothesized that the inhalation of H. pylori or its endotoxins
into the respiratory tract could lead to a chronic activation of inflammatory mediators. In
1998, Tsang et al. first described a significantly higher serum IgG positivity against H. pylori
in 100 consecutive patients with bronchiectasis compared to healthy controls (76.0% vs.
54.3% respectively, p = 0.001) [40]. The following year, Tsang et al. reported a higher
H. pylori CagA+ seroprevalence in bronchiectasis patients than in controls (24% vs. 11.7%,
p = 0.03) [41]. However, Angrill et al. were unable to detect H. pylori by histochemical
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and immunochemical staining in bronchial tissue from patients with bronchiectasis and
positive serology [42]. Similarly, Gülhan et al. did not find evidence of H. pylori DNA in
either BAL fluid or in lung tissues by using PCR, from patients with bronchiectasis. In
addition, they did not find a statistically significant difference in anti-H. pylori IgG level
between patients and controls [43]. Furthermore, in another study, there were no significant
differences between bronchiectasis patients and controls regarding H. pylori positivity in
BAL fluid, gastric juice, and urea breath test [44].
3.4. H. pylori Infection and Lung Cancer
Lung cancer represents a major health problem and is the leading cause of cancer
deaths worldwide. It is mostly caused by inhalation of environmental carcinogens, but
10–15% of cases in Western countries and up to 25% of cases in Asia are diagnosed in
never-smoker subjects [45].
The potential role of chronic infections and inflammation in the stages of carcino-
genesis have been widely investigated for many years, but evidence on the relationship
between H. pylori infection and risk of lung cancer is still controversial, with a limited
number of underpowered studies reporting contrasting results. Two case-control studies,
conducted by Philippou et al. [46] and Najafizadeh et al. [47], showed no significant associ-
ation between H. pylori infection and lung cancer. Another case-control study compared
700 lung cancer patients (350 lung adenocarcinoma cases and 350 squamous cell carcinoma
cases) with 700 controls, showing no significant association between H. pylori seropositivity
and adenocarcinoma (OR = 1.1, 95% CI: 0.75–1.6) or squamous cell carcinoma (OR = 1.1,
95% CI: 0.77–1.7). Similar results were reported for CagA− and CagA+ H. pylori seropos-
itivity [48]. On the other hand, other case-control studies revealed significantly higher
rates of seropositivity for antibodies against H. pylori in patients with lung cancer than
in controls [49–51]. A meta-analysis, published in 2013, included the above-mentioned
studies and calculated the pooled OR [52]. A significantly increased risk of lung cancer in
patients with H. pylori infection (pooled OR = 2.29, 95% CI: 1.34–3.91, p = 0.01) was reported.
The authors, thus, concluded that the results should be interpreted cautiously due to the
inclusion of underpowered studies.
3.5. H. pylori Infection and Tuberculosis
Tuberculosis (TB) is a chronic infectious disease sustained by the bacterium Mycobac-
terium tuberculosis (M. tuberculosis), which generally affects the lungs but can also involve
other organs. Current estimates are that about one-third of the world population is infected
by M. tuberculosis. Nevertheless, infected people without active disease are considered
latent TB cases [53].
In 1992, Mitchell et al. reported that a previous history of active pulmonary TB might
be associated with H. pylori infection in southern China [54]. Subsequently, Filippou et al.
assessed the seroprevalence of H. pylori in a cohort of 80 TB patients before starting anti-
tuberculosis therapy. These authors observed a seroprevalence of 87.5% in the TB group
compared to 61.4% among controls (p < 0.004) [55]. Sanaka et al. showed opposite results
in a serology-based case-control study. No significant difference in H. pylori seroprevalence
was found when comparing 40 inpatients treated with anti-tuberculosis chemotherapy
for no more than 3 months, 43 TB patients on chemotherapy for more than 3 months, and
60 controls (73.3%, 65% and 69.8%, respectively) [56]. However, a potential confounding
factor could be represented by the possible eradication of H. pylori by anti-tuberculosis
drugs, such as rifampicin, streptomycin and rifabutin [57,58]. Furthermore, published
studies included mainly patients with active TB, who usually represent a small proportion
(about 20%) of those with M. tuberculosis infection. Thus, any potential association might
have been masked.
Bustamante-Rengifo et al. proposed two hypothetical models to explain the possible
interaction between H. pylori and M. tuberculosis. In the first one, the H. pylori vacuolating
cytotoxin that interferes with the maturation of dendritic cells and antigen-presenting cells
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as well as inhibits the proliferation of T lymphocytes could be involved. This compromises
CD4+ T cell-activation which could affect susceptibility to acquiring M. tuberculosis. In
the second model, regulatory T (Treg) cells induced by H. pylori could downregulate Th1
and Th17 responses, thus affecting host immunity against M. tuberculosis [53]. Increased
predisposition to H. pylori infection and enhanced mycobacterial survival and replication,
hypothesized in TB patients, may be sustained by the same HLA-DQ serotype, hence
inducing susceptibility to both bacteria [59,60].
3.6. H. pylori Infection and Cystic Fibrosis
Cystic fibrosis is a progressive inherited multisystem disease that affects primarily the
lungs and the digestive system. It is known that in this disease, mutations in the cystic fibro-
sis transmembrane conductance regulator (CFTR) are associated with dysfunction in CFTR
protein. This leads to changes in mucus that becomes thick and sticky in various organs.
Few studies have examined a possible correlation between H. pylori and cystic fibrosis.
Drzymała-Czyż et al. assessed the prevalence of H. pylori infection, using breath tests
with isotope-labeled urea in 79 cystic fibrosis patients compared to 302 healthy controls,
but no significant difference was found [61]. In a study by Yahav et al., the authors
found a lower prevalence of H. pylori infection in cystic fibrosis patients than in non-cystic
fibrosis controls (16.6% and 30.0%, respectively), assessed by using specific monoclonal
antibodies for fecal H. pylori antigen. However, due to the small number of cystic fibrosis
patients enrolled (n = 30) in this study, the difference was not statistically significant [62].
A seroprevalence study, conducted by Israel et al., included 70 cystic fibrosis patients. The
authors reported an initial seropositivity rate of 47% (33/70) for H. pylori IgG antibody, but
after pre-adsorption of these sera with Pseudomonas proteins, a marked decrease in H. pylori
seropositivity (8%, 6/70) was observed, highlighting a cross-reactivity between H. pylori
antigens and Pseudomonas antibodies [63].
Interesting findings arose from basic research. Wen et al. reported a relationship be-
tween H. pylori infection and CFTR downregulation in human duodenal epithelial cells. The
authors found that this event occurred through an increase in transforming growth factor-β
production. The latter induced the phosphorylation of p38 mitogen-activated protein
kinase [64]. This link between H. pylori infection and CFTR downregulation has triggered
scientific interest in understanding whether the microorganism could be involved in some
step of the pathogenesis of cystic fibrosis-induced gastrointestinal and extra-gastrointestinal
damage and whether its eradication could reverse this CFTR expression status.
3.7. H. pylori Infection and Sarcoidosis
Sarcoidosis is an inflammatory disease characterized by the development and growth
of granulomas that affects, in most cases, the lungs and lymph glands. Gastrointestinal
involvement of sarcoidosis is rare but when it occurs, gastric localization is the most
common effect [65]. The cause of sarcoidosis is unknown but it has been hypothesized that
a ubiquitous trigger (chemical, infectious or environmental agent) in genetically susceptible
individuals could induce an altered immune response leading to the disease [66].
There are only few reports regarding a possible association between H. pylori and
sarcoidosis, without any clear causal relationship. Herndon et al. found an increased
incidence of specific H. pylori and urease IgG antibodies in sarcoidosis patients compared
to controls [67]. Koyama et al. reported the presence of H. pylori in a patient with idiopathic
granulomatous gastritis [68], although the granulomatous lesion took several months to
heal after bacterial eradication. In another case report, a subject with symptomatic gastric
sarcoidosis was misdiagnosed as PUD and confounded by H. pylori infection [69]. So far,
the evidence of an etiopathogenetic relationship between the bacterium and gastric or
extra-gastric sarcoidosis is missing.
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4. Discussion
In recent years, several studies have evaluated the possible relationship between
H. pylori infection and various respiratory disorders, such as bronchial asthma, COPD,
bronchiectasis, lung cancer, TB, cystic fibrosis and sarcoidosis. For many of these, a
causal relationship has not been confirmed, primarily due to some important sources
of heterogeneity: the limitations due to epidemiological design of the studies, the low
consideration of confounding variables, lack of appropriate controls and the methods used
to assess H. pylori infection.
Considering study designs, most of the available literature is based on case-control
studies (which could never prove a causal relationship) with small sample sizes (and
consequent increased risk of type II error). Only prospective studies provide a direct
estimate of the risk of developing disease in subjects with a certain characteristic relative
to those without that characteristic. None of the studies investigating the relationship
between H. pylori infection and respiratory diseases in humans is prospective or based on
the criteria proposed to consider a causal role for an agent, i.e., temporality or presence
of the cause before onset of the disease [70]. However, as H. pylori infection is acquired
during childhood and lasts for decades [5], and since most of the respiratory diseases have
a late onset in life, it can be objected that H. pylori infection is most likely to precede the
occurrence of the disease.
Confounders (either in cases or in the control population) represent another possible
influencing variable. For example, low socio-economic status is related to both H. pylori
infection [71] and risk of developing chronic bronchitis [72], but as the bacterium is ac-
quired during childhood, matching for socio-economic status should be performed during
childhood and not at the time of the study. Tobacco use represents another possible con-
founder: it is well known that the prevalence of COPD [72] and lung cancer [73] is higher
in smokers, whereas variable prevalence of H. pylori infection in smokers has been reported.
Thus, the possible impact of cigarette smoking on this type of respiratory diseases and
H. pylori infection should be regarded as a potential study limitation.
The methods used to diagnose H. pylori infection can be classified as invasive or
non-invasive, the former being based on biopsy specimens obtained at endoscopy. The
choice of the test depends on the clinical context. These methods vary in sensitivity and
specificity, which may lead to misclassification biases. Endoscopic-based tests have a
sensitivity depending on the number of bioptic samples obtained during endoscopy, the
gastric site of collection, and the consideration of taking drugs that could influence the
location of the bacterium in the stomach [74]. Among non-invasive tests, urea breath tests
and stool antigen tests both have high sensitivity and specificity (above 90%), whereas
serologic testing for H. pylori IgG has a specificity of less than 80% for active H. pylori
infection [5,75] due to antibodies persistence for years. For this reason, the presence of
these antibodies should be considered a marker of exposure rather than a marker of ongoing
infection, limiting their use in clinical practice due to the risk of treating patients without
previous exposure. Nevertheless, as mentioned above, most of the available literature
on the relationship between respiratory manifestations and H. pylori infection is based
on seroprevalence studies that are considered appropriate from an epidemiological point
of view.
The mechanisms that could correlate respiratory diseases with H. pylori infection
are still unclear, but several hypotheses have been formulated (Figure 3): host immune
response to the bacterium that could induce gastric and extra-gastric tissue damage, molec-
ular mimicry that can result in the cross-activation of autoreactive T or B cells by bacterial
components, and direct damage with chronic airway inflammation by bacterium aspira-
tion or inhalation. H. pylori stimulates humoral, adaptive, local, and systemic immune
response. The potential involvement of the microorganism in the pathogenesis of extra-
gastroduodenal diseases via systemic immune response is supported by the evidence that
the long-term inflammation generated by H. pylori might raise cytokine levels (IL-1, IL-4,
IL-8, IL-10 and tumor necrosis factor-α) in the bloodstream [76]. Furthermore, studies
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involving animal models have shown that this increase occurred not only in serum but
also in the lung tissue of infected mice, together with an increase in metalloproteinases
and markers of endothelial dysfunction such as intracellular adhesion molecule-1 and
intracellular adhesion molecule-5, involved in leukocyte adhesion and migration into the
sub-endothelium. On the contrary, lungs from non-infected animals did not show these
alterations [12]. This could reflect the genetic modification occurring in the lung as a result
of gastric H. pylori infection. In particular, in mice, it has been shown that while in the ab-
sence of a local inducing agent, genes classically involved in pathogen recognition (Smad3
and Smad5) were not affected in the lung, and in the case of gastric H. pylori infection,
the expression of these genes was downregulated in the stomach and increased in the
lung. As a consequence, expression of the SMAD protein plays a crucial role in Th cell
differentiation [77]. The autoimmune mechanism, based on molecular mimicry between
H. pylori lipopolysaccharides and the host tissues, has been demonstrated in the stomach
and could also be involved in extra-gastrointestinal manifestations associated with this
infection. The hypothesis of the induction by H. pylori of anti-self reactions was proposed
after antibodies with reactivity to the gastric mucosa were detected in the sera of infected
patients [78–81].
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Some consistent results showed a possible negative association between H. pylori
and risk for childhoo asthma, particularly in the case of more virulent strains [17]. The
“hygiene hypothesis”, according to which infectious diseases can inhibit allergic Th2
pathways, thus eliciting a Th1 immune response, has been proposed [21]. However, as
discussed above, studi c ducted in po ulations with poor hygiene and low H. pylori
prevalence id not support this model. Finally, the possible inverse co relation between
H. pylori infection and GERD has also been suppo d, as this condition can worsen asthma,
and the latter is a risk factor for developing GERD [22,23]. However, none of these possible
mechanisms, or other aspects, such as genetic predisposition and the impact of H. pylori
eradication on asthma incidence, have been studied in detail.
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An intriguing field of interest involves both the potential role of the airway’s micro-
biota in the host’s local immune regulation and their contribution in the pathogenesis of
respiratory tract diseases [82]. In this context, the potential influence of this microbial
community on the systemic consequences of H. pylori infection remains to be elucidated.
A limitation of our study is the exclusive use of MEDLINE database for conducting
our literature search. This database, which is the primary component of PubMed, is a great
resource for medical research because it contains more than 30 million references to journal
articles. Furthermore, MEDLINE is accessed for free and permits the visualization of online
early versions before print publication by various journals [83]. The associated use of Web
of Science and Scopus databases would have allowed a more complete collection of data.
However, since this is a narrative review, there is less of a risk of influencing the results
compared to a systematic review.
5. Conclusions
The question as to whether H. pylori is an innocent bystander, a protective agent or a
trigger of respiratory diseases cannot yet be answered. On the other hand, these are often
multifaceted disorders, the mechanism of which cannot be explained by only one cause.
Hence, the need for larger studies with appropriate epidemiological design to investigate a
potential causal relationship between H. pylori infection and respiratory diseases is evident.
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